Caribou Biosciences Halts Two CAR-T Trials, Cuts Workforce

What happened

Caribou Biosciences, Inc., a Berkeley, California-based biotechnology company listed on the Nasdaq Global Select Market under the ticker CRBU, disclosed in a Form 8-K filed October 6, 2026 that its board of directors approved a restructuring on October 2, 2026.

According to the filing, the restructuring includes the planned discontinuation of clinical trials and further development of the company's two allogeneic CAR-T cell therapy programs: vispacabtagene regedleucel, or vispa-cel, for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011 for relapsed or refractory multiple myeloma. It also includes a substantial reduction in the company's workforce and other cost reduction measures.

The company said the workforce reduction is expected to occur in phases, with most affected employees departing in the fourth quarter of 2026 and a limited number remaining through completion of the strategic-alternatives process to support transaction execution and business wind-down. The filing does not state how many employees will be affected.

Caribou also disclosed that its board approved a process to evaluate strategic alternatives to maximize stockholder value, including a merger, acquisition, business combination, or other strategic transactions. The board formed a Transaction Committee, and Wedbush Securities Inc. was engaged as exclusive financial advisor. The company said it has not set a timeline for completing the review and does not intend to provide further updates unless and until the board approves a course of action, the review concludes, or disclosure is otherwise required.

Costs and the CFO's employment

Caribou estimated it will incur approximately $15 million to $19 million in total expenses related to the restructuring, a substantial portion expected to be recognized in the fourth quarter of 2026. Those anticipated expenses include approximately $10 million to $11 million for one-time severance payments, continued healthcare coverage, and related costs, plus $5 million to $8 million to wind down the ANTLER phase 1 and CaMMouflage phase 1 clinical trials.

The company said it intends to terminate applicable contracts, resolve intellectual property licensing arrangements, and seek ways to sublease its facilities or terminate facility leases. It said it cannot currently make a good-faith estimate of other charges, including facility lease charges, contract termination costs, or asset impairments, and will file an amendment to the Form 8-K within four business days after making such a determination. The filing notes the company has an ongoing long-term follow-up study for patients previously treated with any investigational product candidate.

Separately, the filing states that the employment of Chief Financial Officer Sriram Ryali will terminate on the date the company executes a binding definitive agreement for a strategic alternative, and that the termination would be treated as "without cause" under his employment agreement dated January 2, 2025. Under that agreement, Ryali would be entitled to the severance payments and benefits it provides. The agreement was filed as Exhibit 10.51 to the company's annual report on Form 10-K for the year ended December 31, 2024.

Why the company said it acted

The filing attributes the board's decisions to the current financing environment for allogeneic CAR-T cell therapies, which the company said has made it increasingly challenging to secure the capital necessary to responsibly advance its programs. That is the only reason given in the filing for the discontinuation and restructuring.

The filing does not provide the company's cash balance, its cash runway, or details on any specific financing attempt. It also does not state whether any party has expressed interest in acquiring the company or its assets.

Market reaction

The stock closed at $1.135 on the event date, down 4.62% from the previous close of $1.19, according to the price data. Volume was 4,642,000 shares, about 3.92 times the average volume of 1,182,828, a move the data characterizes as roughly 6.45 standard deviations from normal. The price data alone does not establish what caused the move.

What this means

A Form 8-K is a "current report." Public companies file one when something material happens between quarterly reports, rather than waiting for the next 10-Q or 10-K. Companies check boxes that correspond to numbered items, so readers can tell what kind of event is being disclosed. This filing carries four: Item 2.05 for costs associated with exit or disposal activities, which covers restructurings and their expected charges; Item 5.02 for the departure or change of directors and certain officers, which is what triggers disclosure of Ryali's termination terms; Item 7.01 for Regulation FD disclosure, used when a company gives material information to the public selectively; and Item 8.01 for other events, which does not fit a specific category. Item 9.01 is the exhibit list. The press release is attached as Exhibit 99.1.

Item 7.01 matters for a mechanical reason. Regulation FD, or Fair Disclosure, bars companies from giving material information privately to analysts or large investors before the public. The wording in the filing — that the information is "furnished" and not "filed," and is not subject to liability under Section 18 of the Securities Exchange Act — is standard. Furnished material is not automatically incorporated into other filings and carries a different legal status than filed material.

The two discontinued programs are allogeneic CAR-T therapies. CAR-T is a treatment in which a patient's own T cells, part of the immune system, are engineered to recognize and attack cancer. "Allogeneic" means the cells come from a donor rather than the patient, which would allow an off-the-shelf product instead of a personalized one. Viscabtagene regedleucel is the full scientific name of vispa-cel. The two trials being wound down, ANTLER and CaMMouflage, were each in phase 1, the earliest stage of human testing, where the primary questions are safety and dosing.

The accounting items have specific meanings. An asset impairment is a write-down of the recorded value of something the company owns — laboratory equipment, for instance — when that value is no longer supported. Resolving an intellectual property licensing arrangement means ending a contract under which the company had rights to use someone else's patented technology, usually with a termination payment or renegotiated terms. Because the company said it cannot yet estimate lease, contract, and impairment charges, it committed to filing an amendment to this Form 8-K within four business days of making that determination — that is a defined obligation under the item, not a forecast.

A strategic alternatives process is the standard corporate phrase for a review that can end in a sale of the company, a sale of assets, a merger, a partnership, or, just as often, no transaction at all. The company engaged an investment bank to run the process and formed a board committee to oversee it. The filing states plainly that Caribou has not set a timeline and cannot commit to whether the process will produce any transaction. That statement is the company's own language, and it is the reason there is no predictable next step: the filing says further updates will come only if the board approves a course of action or the review concludes.